© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Endonovo Therapeutics, Inc. (ENDV) stock remained unchanged at $0.00 a share on OTC. The stock opened at $0.00, fluctuating between $0.00 to $0.00 during the session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 1M |
| Sep 09, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 1.5M |
| Sep 08, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 100 |
| Sep 03, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 500K |
| Sep 02, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 500.21K |
| Sep 01, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 500K |
| Aug 31, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 1.5M |
| Aug 26, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 500K |
| Aug 24, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 0 |
| Aug 19, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 500K |
| Aug 17, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 500K |
| Aug 14, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 1.6M |
| Aug 13, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 500K |
| Aug 12, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 1M |
| Aug 11, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 1.5M |
| Aug 10, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 2M |
| Aug 03, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 1M |
| Jul 31, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 100 |
| Jul 23, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 10.01K |
| Jul 21, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 1M |
Endonovo Therapeutics, Inc., a biotechnology company, specializes in the development, manufacturing, and distribution of non-invasive electroceutical medical devices designed for regenerative medicine applications. The company's primary offering is SofPulse, an advanced non-invasive therapeutic device that employs electroceutical technology. SofPulse is engineered to provide palliative relief for various conditions, including soft tissue injuries, chronic wounds, and post-operative pain and edema. Beyond these applications, Endonovo's electroceutical medical device is also utilized in treating a broad spectrum of other ailments. These include inflammation, various types of wounds, cardiovascular diseases, chronic kidney and liver disorders (such as non-alcoholic steatohepatitis), peripheral artery diseases, and ischemic stroke. Furthermore, its technology is deployed in managing central nervous system disorders like traumatic brain injury, acute concussions, post-concussion syndrome, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and maintains its headquarters in Woodland Hills, California.
| Employees | 1 |
| Beta | -8.04 |
| Sales or Revenue | $140.24K |
| 5Y Sales Change% | -0.998% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |